Actualités HeartSciences Inc - HSCS | Actions NASDAQ

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or...

HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:...

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:...

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:...

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:...

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Southlake, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences...

HeartSciences Regains Compliance with Nasdaq Listing Requirements

Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:...

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:...

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Southlake, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences...

HeartSciences to Present at the LD Micro Invitational XIV Conference

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences...

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

HeartSciences Inc (HSCS)

Votre Hub pour des idées et discussions en direct en temps réel

HSCS Actualités

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

HeartSciences Regains Compliance with Nasdaq Listing Requirements

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

HeartSciences to Present at the LD Micro Invitational XIV Conference

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

HeartSciences Inc (HSCS) Actualités

HeartSciences Inc (HSCS)

Votre Hub pour des idées et discussions en direct en temps réel

HSCS Actualités

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

HeartSciences Regains Compliance with Nasdaq Listing Requirements

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

HeartSciences to Present at the LD Micro Invitational XIV Conference

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application